US FDA accepts new drug application for GSKs momelotinib for the treatment of myelofibrosis

Regulatory submission included data from the pivotal MOMENTUM phase III clinical trial that met all primary and key secondary efficacy endpoints.

Related Keywords

United States ,American , ,American Society Of Clinical Oncology Annual Meeting ,Sierra Oncology Inc ,European Hematology Association ,Drug Administration ,New Drug Application ,Prescription Drug User Fee Act ,Total Symptom Score ,Transfusion Independence ,Splenic Response Rate ,Clinical Oncology Annual Meeting ,Myelofibrosis Symptom Assessment ,Sierra Oncology ,Hematol Oncol ,Myelofibrosis Related Anemia ,Emerging Therapeutic ,Congress ,Disease ,Medicine ,Merger And Acquisition ,Nasdaq ,Pharmaceuticals ,Chemical Compounds ,Hepcidin ,Janus Kinase Inhibitor ,Momelotinib ,Morpholines ,Myelofibrosis ,Nitriles ,Organic Compounds ,Pyrazoles ,Ruxolitinib ,Teratogens ,